卡培他滨联合吉西他滨或长春瑞滨治疗复发转移性乳腺癌的疗效观察

Capecitabin combined with gemcitabine/vinorelbine in treatment of patients with recurrent metastatic breast cancer

目的观察吉西他滨或长春瑞滨联合卡培他滨方案治疗复发转移性乳腺癌患者的疗效。方法本研究纳入2008年1月1日-2014年5月1日解放军总医院收治的采用吉西他滨或长春瑞滨联合卡培他滨方案治疗的75例女性晚期乳腺癌患者,42例接受卡培他滨联合吉西他滨（GX）方案治疗,33例接受卡培他滨联合长春瑞滨（NX）方案治疗。结果 GX方案组客观有效率为16.7%,疾病控制率为85.7%,临床获益率为45.2%,肿瘤进展时间为5.68个月（95%CI：3.679~7.689）;NX方案组客观有效率为29.3%,疾病控制率为74.8%,临床获益率为51.5%,肿瘤进展时间为8.25个月（95%CI：3.717~12.776）,NX方案用于一线化疗疗效优于二线或以上化疗疗效。结论 NX方案在晚期患者的治疗中用于一线化疗疗效更佳;GX方案在后续多线化疗中也可取得较好疗效。

Objective To evaluate the efficacy of gemcitabine/vinorelbine combined with capecitabin in treatment of patients with recurrent metastatic breast cancer. Methods Seventy-five patients diagnosed with recurrent metastatic breast cancer in Chinese PLA General Hospital from January 1, 2008 to May 1, 2014 were enrolled in this study. Of the 75 cases, 42 patients were treated with gemcitabine and capecitabin（GX）, 33 patients were treated with vinorelbine and capecitabin（NX）. Results In GX regimen group, the objective response rate was 16.7%, the disease control rate was 85.7%, the clinical benefit rate was 45.2%, and the timeto-progression was 5.68（95% CI： 3.679-7.689） months. In NX regimen group, the objective response rate was 29.3%, the disease control rate was 74.8%, the clinical benefit rate was 51.5%, and the time-to-progression was 8.25（95% CI： 3.717-12.776） months. The efficacy of NX regimen in first-line chemotherapy was superior to multi-line chemotherapy. Conclusion Both treatments are well tolerated. NX regimen may have a better efficacy in first-line chemotherapy.